Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The 1+1 protocol is a patient-driven intravenous hydromorphone titration strategy developed by researchers at Montefiore Medical Center for the management of acute severe pain in emergency department patients. The protocol involves an initial 1 mg dose of IV hydromorphone, followed by a mandatory assessment 15 minutes later. At this interval, the patient is asked, "Do you want more pain medication?" If the patient answers "yes," a second 1 mg dose is administered. This approach is designed to provide efficacious analgesia while allowing for individual variation in opioid requirements and minimizing the risk of over-sedation or respiratory depression. It has been studied in Phase 3 clinical trials, comparing its efficacy and safety against fixed-dose bolus regimens (such as 2 mg IV hydromorphone) and traditional physician-directed care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1+1 hydromorphone protocol.